RESUMO
OBJECTIVE: Older people with multiple sclerosis (MS) have a less active radiological and clinical presentation, but many still attain significant levels of disability; but what drives worsening disability in this group? METHODS: We used data from the UK MS Register to characterize demographics and clinical features of late-onset multiple sclerosis (LOMS; symptom onset at ≥50 years), compared with adult-onset MS (AOMS; onset 18-49 years). We performed a pathology study of a separate MS cohort with a later onset (n = 18, mean age of onset 54 years) versus AOMS (n = 23, mean age of onset 29 years). RESULTS: In the Register cohort, there were 1,608 (9.4%) with LOMS. When compared with AOMS, there was a lower proportion of women, a higher proportion of primary progressive MS, a higher level of disability at diagnosis (median MS impact scale 36.7 vs. 28.3, p < 0.001), and a higher proportion of gait-related initial symptoms. People with LOMS were less likely to receive a high efficacy disease-modifying treatment and attained substantial disability sooner. Controlling for age of death and sex, neuron density in the thalamus and pons decreased with onset-age, whereas actively demyelinating lesions and compartmentalized inflammation was greatest in AOMS. Only neuron density, and not demyelination or the extent of compartmentalized inflammation, correlated with disability outcomes in older-onset MS patients. INTERPRETATION: The more progressive nature of older-onset MS is associated with significant neurodegeneration, but infrequent inflammatory demyelination. These findings have implications for the assessment and treatment of MS in older people. ANN NEUROL 2024;95:471-486.
Assuntos
Esclerose Múltipla , Patologia Clínica , Adulto , Humanos , Feminino , Idoso , Pessoa de Meia-Idade , Esclerose Múltipla/epidemiologia , Esclerose Múltipla/diagnóstico , Estudos de Coortes , Idade de Início , Progressão da Doença , Inflamação , DemografiaRESUMO
AIMS: We sought to determine whether intraplaque inflammation could be measured with positron emission tomography/computed tomography angiography (PET/CTA) using (11)C-PK11195, a selective ligand of the translocator protein (18 kDa) (TSPO) which is highly expressed by activated macrophages. METHODS AND RESULTS: Patients (n = 32; mean age 70 ± 9 years) with carotid stenoses (n = 36; 9 symptomatic and 27 asymptomatic) underwent (11)C-PK11195 PET/CTA imaging. (11)C-PK11195 uptake into carotid plaques was measured using target-to-background ratios (TBR). On CTA images, plaque composition was assessed by measuring CT attenuation of the carotid plaque. Eight patients underwent carotid endarterectomy and ultrathin contiguous sections were processed for TSPO and CD68 (using immunohistochemical staining, (3)H-PK11195 autoradiography, and confocal fluorescence microscopy). Carotid plaques associated with ipsilateral symptoms (stroke or transient ischaemic attack) had higher TBR (1.06 ± 0.20 vs. 0.86 ± 0.11, P = 0.001) and lower CT attenuation [(median, inter-quartile range) 37, 24-40 vs. 71, 56-125 HU, P = 0.01] than those without. On immunohistochemistry and confocal fluorescence microscopy, CD68 and PBR co-localized with (3)H-PK11195 uptake at autoradiography. There was a significant correlation between (11)C-PK11195 TBR and autoradiographic percentage-specific binding (r = 0.77, P = 0.025). Both TBR and CT plaque attenuation had high negative predictive values (91 and 92%, respectively) for detecting symptomatic patients. However, the best positive predictive value (100%) was achieved when TBR and CT attenuation were combined. CONCLUSION: Imaging intraplaque inflammation in vivo with (11)C-PK11195 PET/CTA is feasible and can distinguish between recently symptomatic and asymptomatic plaques. Patients with a recent ischaemic event had ipsilateral plaques with lower CT attenuation and increased (11)C-PK11195 uptake.
Assuntos
Doenças das Artérias Carótidas/diagnóstico por imagem , Estenose das Carótidas/diagnóstico por imagem , Isoquinolinas , Imagem Multimodal/métodos , Tomografia por Emissão de Pósitrons , Compostos Radiofarmacêuticos , Tomografia Computadorizada por Raios X , Idoso , Autorradiografia , Radioisótopos de Carbono , Feminino , Humanos , Imuno-Histoquímica , Masculino , Microscopia de Fluorescência , Pessoa de Meia-IdadeRESUMO
BACKGROUND AND PURPOSE: Development of translational functional imaging modalities for atherosclerosis risk stratification is sought for stroke prediction. Our group has developed late-phase contrast-enhanced ultrasound (LP-CEUS) to quantify microbubble contrast retention within carotid atherosclerosis and shown it to separate asymptomatic plaques from those responsible for recent cerebrovascular events. We hypothesized that microbubbles are retained in areas of plaque inflammation, aiming to examine whether LP-CEUS signal reflects plaque biology. METHODS: Subjects awaiting carotid endarterectomy (n=31) underwent axial LP-CEUS and diseased intimal segments were symmetrically divided in the long axis. Half-specimens underwent quantitative immunohistochemical analysis for CD68 (macrophages) and CD31 (angiogenesis). Half-specimens were processed for atheroma cell culture and supernatant collected at 24 hours for multianalyte profiling for 34 analytes. RESULTS: Percentage area immunopositivity was significantly higher in subjects in which normalized plaque late-phase intensity was ≥0 versus <0 (CD68 mean 11.8 versus 6.68, P=0.004; CD31 mean 9.45 versus 4.82, P=0.025). Interleukin-6, matrix metalloproteinase-1, and matrix metalloproteinase-3 were significantly higher by multianalyte profiling when LP-CEUS was ≥0. CONCLUSIONS: LP-CEUS reflects biological features of inflammation and angiogenesis, key features predisposing to plaque rupture. Further investigation of LP-CEUS as a tissue-specific marker of inflammation for risk stratification of carotid atherosclerosis is warranted.
Assuntos
Aterosclerose/diagnóstico por imagem , Artérias Carótidas/diagnóstico por imagem , Doenças das Artérias Carótidas/diagnóstico por imagem , Estenose das Carótidas/diagnóstico por imagem , Idoso , Aterosclerose/cirurgia , Artérias Carótidas/cirurgia , Doenças das Artérias Carótidas/cirurgia , Estenose das Carótidas/cirurgia , Endarterectomia das Carótidas , Feminino , Humanos , Inflamação/diagnóstico por imagem , Inflamação/cirurgia , Masculino , Microbolhas , UltrassonografiaRESUMO
PURPOSE: To combine a motion-sensitized driven equilibrium (MSDE) preparation with a multi-echo spoiled gradient-echo sequence (SPGR) to suppress the blood signal intensity in T2* mapping of carotid plaques and liver. MATERIALS AND METHODS: The analytical solution of the Bloch equations for the multi-echo SPGR sequence, with and without the MSDE preparation, was calculated to optimize sequence parameters. The sequence was implemented at 3 Tesla and T2* maps of carotid plaques and liver were first optimized for blood suppression, and then acquired from five healthy livers and six subjects with ultrasound-identified carotid plaques. RESULTS: Simulations and experimental data showed that the flip angle that gives maximal signal (Ernst angle) in the MSDE-SPGR was greatly increased from that of pure SPGR. Robust blood suppression was obtained in the T2* maps of carotid plaques and liver, requiring suppression at a field of speed (FOS) of 30 cm/s in both the carotids and liver. CONCLUSION: MSDE provides a means to suppress the blood signal intensity in SPGR sequences. Tissue T2* maps can be obtained without the confounding effects originating from blood vessels.
Assuntos
Artefatos , Estenose das Carótidas/sangue , Estenose das Carótidas/patologia , Interpretação de Imagem Assistida por Computador/métodos , Fígado/irrigação sanguínea , Imageamento por Ressonância Magnética/métodos , Técnica de Subtração , Algoritmos , Humanos , Aumento da Imagem/métodos , Fígado/anatomia & histologia , Movimento (Física) , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
Magnetic resonance imaging (MRI) has had a profound impact on both research and clinical management of multiple sclerosis (MS), but signal changes reflect underlying neuropathology only indirectly and often non-specifically. Positron emission tomography (PET) offers the potential to complement MRI with quantitative measures of molecularly specific markers of cellular and metabolic processes. PET radiotracers already available promise new insights into the dynamics of the innate immune response, neuronal function, neurodegeneration and remyelination. Because PET is an exquisitely sensitive technique (able to image even picomolar concentrations), only microdoses of radioligand (<10 µg) are needed for imaging. This facilitates rapid implementation of novel radioligands because extensive toxicology data is not required. In the future, molecular imaging could assist clinical decision-making with patient stratification for optimization of treatment selection.
Assuntos
Encéfalo/diagnóstico por imagem , Imagem Molecular/métodos , Esclerose Múltipla/diagnóstico por imagem , Tomografia por Emissão de Pósitrons , Compostos Radiofarmacêuticos , Biomarcadores/análise , Encéfalo/metabolismo , Humanos , Imageamento por Ressonância Magnética , Esclerose Múltipla/metabolismo , Valor Preditivo dos Testes , Prognóstico , Sensibilidade e Especificidade , Índice de Gravidade de DoençaRESUMO
[This corrects the article DOI: 10.3389/fimmu.2019.00790.].
RESUMO
Microglia are resident macrophages of the central nervous system and significantly contribute to overall brain function by participating in phagocytosis during development, homeostasis, and diseased states. Phagocytosis is a highly complex process that is specialized for the uptake and removal of opsonized and non-opsonized targets, such as pathogens, apoptotic cells, and cellular debris. While the role of phagocytosis in mediating classical innate and adaptive immune responses has been known for decades, it is now appreciated that phagocytosis is also critical throughout early neural development, homeostasis, and initiating repair mechanisms. As such, modulating phagocytic processes has provided unexplored avenues with the intent of developing novel therapeutics that promote repair and regeneration in the CNS. Here, we review the functional consequences that phagocytosis plays in both the healthy and diseased CNS, and summarize how phagocytosis contributes to overall pathophysiological mechanisms involved in brain injury and repair.
Assuntos
Encéfalo/imunologia , Microglia/imunologia , Fagocitose/imunologia , Animais , Encefalopatias/imunologia , Homeostase/imunologia , Humanos , Macrófagos/imunologia , Fagócitos/imunologiaRESUMO
Microglia are rapidly activated by a wide range of neuropathological insults. Quantifying microglial density in vivo would allow a new, potentially important range of clinic-pathological correlations. Microglia express the 18kDa translocator protein (TSPO) which can be quantified by the positron emission tomography (PET) ligand [(11)C]PK11195, although signal quantification is limited by nonspecific binding. New generation TSPO radioligands with an improved signal-to-noise ratio are now available, but variation in their binding affinity for the TSPO between subjects complicates their use. This review describes the principles of PET imaging, the rationale and challenges in targeting the TSPO as means of quantifying microglial activation in vivo, and disease applications that have been studied with TSPO-PET hitherto.
Assuntos
Química Encefálica/fisiologia , Microglia/metabolismo , Tomografia por Emissão de Pósitrons/métodos , Ensaio Radioligante/métodos , Receptores de GABA/análise , Receptores de GABA/metabolismo , Biomarcadores/metabolismo , Humanos , Microglia/fisiologia , Neuroimagem/métodos , Neuroimagem/tendências , Tomografia por Emissão de Pósitrons/tendências , Ensaio Radioligante/tendênciasRESUMO
UNLABELLED: 11C-PBR28 PET can detect the 18-kDa translocator protein (TSPO) expressed within macrophages. However, quantitative evaluation of the signal in brain tissue from donors with multiple sclerosis (MS) shows that PBR28 binds the TSPO with high affinity (binding affinity [Ki], â¼4 nM), low affinity (Ki, â¼200 nM), or mixed affinity (2 sites with Ki, â¼4 nM and â¼300 nM). Our study tested whether similar binding behavior could be detected in brain tissue from donors with no history of neurologic disease, with TSPO-binding PET ligands other than 11C-PBR28, for TSPO present in peripheral blood, and with human brain PET data acquired in vivo with 11C-PBR28. METHODS: The affinity of TSPO ligands was measured in the human brain postmortem from donors with a history of MS (n=13), donors without any history of neurologic disease (n=20), and in platelets from healthy volunteers (n=13). Binding potential estimates from thirty-five 11C-PBR28 PET scans from an independent sample of healthy volunteers were analyzed using a gaussian mixture model. RESULTS: Three binding affinity patterns were found in brains from subjects without neurologic disease in similar proportions to those reported previously from studies of MS brains. TSPO ligands showed substantial differences in affinity between subjects classified as high-affinity binders (HABs) and low-affinity binders (LABs). Differences in affinity between HABs and LABs are approximately 50-fold with PBR28, approximately 17-fold with PBR06, and approximately 4-fold with DAA1106, DPA713, and PBR111. Where differences in affinity between HABs and LABs were low (â¼4-fold), distinct affinities were not resolvable in binding curves for mixed-affinity binders (MABs), which appeared to express 1 class of sites with an affinity approximately equal to the mean of those for HABs and LABs. Mixed-affinity binding was detected in platelets from an independent sample (HAB, 69%; MAB, 31%), although LABs were not detected. Analysis of 11C-PBR28 PET data was not inconsistent with the existence of distinct subpopulations of HABs, MABs, and LABs. CONCLUSION: With the exception of 11C-PK11195, all TSPO PET ligands in current clinical application recognize HABs, LABs, and MABs in brain tissue in vitro. Knowledge of subjects' binding patterns will be required to accurately quantify TSPO expression in vivo using PET.
Assuntos
Acetamidas/metabolismo , Encéfalo/metabolismo , Radioisótopos de Carbono , Piridinas/metabolismo , Ensaio Radioligante/métodos , Receptores de GABA/análise , Ligação Competitiva , Humanos , Isoquinolinas/metabolismo , Peso Molecular , Tomografia por Emissão de PósitronsRESUMO
A novel series of N(1)-methyl-(2-phenylindol-3-yl)glyoxylamides, 19-31, designed in accordance with our previously reported pharmacophore/topological model, showed high affinity for the 18 kDa translocator protein (TSPO) and paved the way for developing a new radiolabeled probe. Thus ligand 31, N,N-di-n-propyl-(N(1)-methyl-2-(4'-nitrophenyl)indol-3-yl)glyoxylamide, featuring the best combination of affinity and lipophilicity, was labeled with carbon-11 for evaluation with positron emission tomography (PET) in monkey. After intravenous injection, [(11)C]31 entered brain to give a high proportion of TSPO-specific binding. These findings augur well for the future application of [(11)C]31 in humans. Consequently, the binding of 31 to human TSPO was tested on samples of brain membranes from deceased subjects who through ethically approved in vitro study had previously been established to be high-affinity binders (HABs), mixed-affinity binders (MABs), or low-affinity binders (LABs) for the known TSPO ligand, PBR28 (2). 31 showed high affinity for HABs, MABs, and LABs. In conclusion, [(11)C]31 represents a promising new chemotype for developing novel TSPO radioligands as biomarkers of neuroinflammation.